Want to see TECH full AI Analyst Report?
EBIT by Segment
Shows how much profit each business unit generates before interest and taxes, highlighting which segments are the most profitable and which may be dragging on overall margins. Useful for spotting where management should focus cost control, pricing power, or investment to drive company-wide earnings.Bio-Techne's Diagnostics and Spatial Biology segment has experienced significant volatility in EBIT, with a notable decline in recent quarters. The latest earnings call highlights challenges in this segment, including order timing issues and geopolitical headwinds. Despite these setbacks, the company is focusing on profitability through strategic divestitures, such as Exosome Diagnostics, which is expected to enhance margins. While the biopharma market shows strength, uncertainties in biotech funding and potential tariff impacts pose risks, suggesting a cautious outlook for sustained EBIT growth in this segment.
Date | Diagnostics and Spatial Biology |
|---|---|
Jun 30, 2025 | $5.38M |
Mar 31, 2025 | $8.42M |
Dec 31, 2024 | $3.24M |
Sep 30, 2024 | $4.28M |
Jun 30, 2024 | $11.36M |
Mar 31, 2024 | $8.10M |
Dec 31, 2023 | $4.56M |
Sep 30, 2023 | $527.00K |
Jun 30, 2023 | $14.64M |
Mar 31, 2023 | $11.46M |